Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(18)30240-7 ◽

2018 ◽

Vol 19 (7) ◽

pp. 889-903 ◽

Cited By ~ 100

Author(s):

Jorge Cortes ◽

Alexander E Perl ◽

Hartmut Döhner ◽

Hagop Kantarjian ◽

Giovanni Martinelli ◽

...

Keyword(s):

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Phase 2 ◽

Open Label ◽

Phase 2 Trial ◽

Flt3 Inhibitor ◽

Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial

10.1016/s2352-3026(21)00192-7 ◽

2021 ◽

Vol 8 (8) ◽

pp. e552-e561 ◽

Cited By ~ 1

Author(s):

Tapan M Kadia ◽

Patrick K Reville ◽

Gautam Borthakur ◽

Musa Yilmaz ◽

Steven Kornblau ◽

...

Keyword(s):

High Risk ◽

Acute Myeloid Leukaemia ◽

Myelodysplastic Syndrome ◽

Myeloid Leukaemia ◽

Intensive Chemotherapy ◽

Phase 2 ◽

Newly Diagnosed ◽

Single Centre ◽

Phase 2 Trial ◽

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)00362-9 ◽

2015 ◽

Vol 16 (16) ◽

pp. 1691-1699 ◽

Cited By ~ 191

Author(s):

Christoph Röllig ◽

Hubert Serve ◽

Andreas Hüttmann ◽

Richard Noppeney ◽

Carsten Müller-Tidow ◽

...

Keyword(s):

Randomised Controlled Trial ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Standard Therapy ◽

Controlled Trial ◽

Phase 2 ◽

Newly Diagnosed ◽

Multicentre Phase ◽

Randomised Controlled ◽

Peripheral blood molecular measurable residual disease is sufficient to identify patients with acute myeloid leukaemia with imminent clinical relapse

British Journal of Haematology ◽

10.1111/bjh.17449 ◽

2021 ◽

Author(s):

Anne‐Sofie Skou ◽

Kristian Løvvik Juul‐Dam ◽

Hans B. Ommen ◽

Henrik Hasle

Keyword(s):

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Peripheral Blood ◽

Residual Disease ◽

Clinical Relapse ◽

Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(13)70037-8 ◽

2013 ◽

Vol 14 (4) ◽

pp. 354-362 ◽

Cited By ~ 26

Author(s):

Jorge Cortes ◽

Eric Feldman ◽

Karen Yee ◽

David Rizzieri ◽

Anjali S Advani ◽

...

Keyword(s):

Elderly Patients ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Phase 2 ◽

Open Label ◽

Phase 2 Study ◽

Open Label Phase ◽

Dosing Regimens ◽

Measurable residual disease testing in acute myeloid leukaemia

Leukemia ◽

10.1038/leu.2017.113 ◽

2017 ◽

Vol 31 (7) ◽

pp. 1482-1490 ◽

Cited By ~ 101

Author(s):

C S Hourigan ◽

R P Gale ◽

N J Gormley ◽

G J Ossenkoppele ◽

R B Walter

Keyword(s):

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Residual Disease ◽

Acute Myeloid ◽

Disease Testing

Measurable residual disease assessment by qPCR in peripheral blood is an informative tool for disease surveillance in childhood acute myeloid leukaemia

British Journal of Haematology ◽

10.1111/bjh.16560 ◽

2020 ◽

Vol 190 (2) ◽

pp. 198-208

Author(s):

Kristian Løvvik Juul‐Dam ◽

Hans B. Ommen ◽

Charlotte G. Nyvold ◽

Christiane Walter ◽

Helen Vålerhaugen ◽

...

Keyword(s):

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Peripheral Blood ◽

Disease Surveillance ◽

Residual Disease ◽

Disease Assessment ◽

Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study

10.1016/s2352-3026(19)30114-0 ◽

2019 ◽

Vol 6 (9) ◽

pp. e480-e488 ◽

Cited By ~ 19

Author(s):

Farhad Ravandi ◽

Rita Assi ◽

Naval Daver ◽

Christopher B Benton ◽

Tapan Kadia ◽

...

Keyword(s):

High Risk ◽

Acute Myeloid Leukaemia ◽

Myelodysplastic Syndrome ◽

Myeloid Leukaemia ◽

Phase 2 ◽

Newly Diagnosed ◽

Phase 2 Study ◽

Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial

10.1016/s2352-3026(17)30228-4 ◽

2018 ◽

Vol 5 (1) ◽

pp. e34-e43 ◽

Cited By ~ 33

Author(s):

Moshe Mittelman ◽

Uwe Platzbecker ◽

Boris Afanasyev ◽

Sebastian Grosicki ◽

Raymond S M Wong ◽

...

Keyword(s):

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Myelodysplastic Syndromes ◽

Severe Thrombocytopenia ◽

Phase 2 ◽

Phase 2 Trial ◽

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

10.1016/s2352-3026(20)30210-6 ◽

2020 ◽

Vol 7 (10) ◽

pp. e724-e736 ◽

Cited By ~ 7

Author(s):

Courtney D DiNardo ◽

Abhishek Maiti ◽

Caitlin R Rausch ◽

Naveen Pemmaraju ◽

Kiran Naqvi ◽

...

Keyword(s):

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Intensive Chemotherapy ◽

Phase 2 ◽

Newly Diagnosed ◽

Single Centre ◽

Phase 2 Trial ◽